It is currently only a preprint on bioRxiv, but it has already attracted significant attention from the scientific community and the journal Science. Mammoth Biosciences, a company founded by CRISPR co-inventor Jennifer Doudna, has developed NanoCas, a mini-editor that is just one-third the size of traditional gene-editing scissors (Cas9).
Continue readingNatural evolution has had four billion years to experiment with living matter. From now on, artificial intelligence will also help expand the catalog of possible and desirable molecules. These so-called ‘language systems’ are no longer limited to producing text or images, as exemplified by ChatGPT or Midjourney. They can now be instructed and utilized to design new proteins, thereby potentially creating improved CRISPR scissors.
Continue reading
CRISPeR Frenzy asked Luigi Naldini of the San Raffaele Telethon Institute for Gene Therapy in Milan for comment on three studies published in June on the preprint server bioRxiv. The experiments were carried out independently by the groups of Kathy Niakan of the Francis Crick Institute in London, Dieter Egli of Columbia University in New York City, and Shoukhrat Mitalipov of Oregon Health & Science University in Portland. These findings heighten safety concerns about heritable genome editing (see the news item by Heidi Ledford in Nature). Below you can read Naldini’s thoughts.
Continue reading
Hopefully, CRISPR-based diagnostics will make an early debut amid COVID-19 outbreak. But what about a CRISPR prophylactic strategy to combat coronaviruses? The proof of concept is here, in bioRxiv, but it will be deployed in the next pandemic if we are lucky. It’s called PAC-MAN, like the videogame, stands for Prophylactic Antiviral CRISPR in huMAN cells, and comes from the Stanley Qi Lab.
Continue reading
The analysis of tweets discussing CRISPR from 2013 to 2019 shows that public enthusiasm for genome editing has cooled a bit, and that’s physiological. As you can see below, a bioRxiv paper associates peaks of strong negative sentiments with specific events.
Continue reading
“Wow! Badass. 13,200 crispr base edits in a single cell! On the way to ‘recoded’ human cells,” tweeted Antonio Regalado before covering the news in MIT Technology Review. To be honest, the radical redesign of species is still sci-fi dystopia, but the paper preprinted by Cory J. Smith et al. in bioRxiv is impressive anyway. Continue reading
Up and down, following the excitement for the latest scientific exploit or frustration for disappointing results. CRISPR is young but already knows how volatile is the market. “Preprint wipes millions off CRISPR companies’ stocks,” cries the March issue of Nature Biotechnology. Continue reading
![crispr-latest-edition[8047]](https://mycrispr.blog/wp-content/uploads/2018/02/crispr-latest-edition8047.jpg)
There is hardly any day without CRISPR news. February starts with researchers correcting abnormalities associated with Duchenne muscular dystrophy (Science Advances) and performing allele-specific editing in blind mice (bioRxiv, forthcoming in The CRISPR Journal). A repechage from January also: how to get pluripotent stem cells by CRISPRing just one gene (Cell Stem Cell).
“Uh Oh. CRISPR might not work on people”. A title like this on the MIT Technology Review website is not the best way to kick-start the new year. But wait, our motto still stands: keep calm and crispr on.
CRISPeR FRENZY 